Key Highlights
- Fayuvi received FDA clearance as the inaugural therapy addressing the underlying cause of Sanfilippo syndrome Type A
- Shares of Ultragenyx (RARE) climbed 13% to reach $14.50 in Thursday’s trading session after the regulatory announcement
- The treatment is delivered as a single-dose gene therapy via intravenous infusion, utilizing a modified viral vector to penetrate brain tissue
- Trial participants receiving the therapy demonstrated a 23.5-point improvement on cognitive assessments compared to the control group
- The approval represents Ultragenyx’s sixth regulatory clearance from the FDA and its second gene therapy product
Ultragenyx (RARE) shares rallied 13% to finish at $14.50 on Thursday following regulatory clearance of Fayuvi, a gene therapy designed to treat Sanfilippo syndrome Type A, a devastating hereditary condition that causes progressive neurological deterioration in pediatric patients.
Ultragenyx Pharmaceutical Inc., RARE
Prior to this regulatory milestone, families had no therapeutic options targeting the fundamental disease mechanism. Medical professionals were limited to treating symptoms as they emerged.
The therapy functions by addressing a deficiency in the sulfamidase enzyme. When this enzyme is absent, heparan sulfate, a complex carbohydrate, accumulates within brain tissue, triggering ongoing cellular destruction and neurological decline.
Administration occurs via a single intravenous infusion delivered into circulation. The treatment employs AAV9, a genetically modified viral vector engineered to penetrate the blood-brain barrier and reach central nervous system tissues.
Regulatory clearance was supported by clinical evidence spanning up to eight years. Pediatric patients receiving Fayuvi demonstrated cognitive test scores averaging 23.5 points higher than those in the untreated comparison group.
Investigators additionally measured heparan sulfate concentrations in cerebrospinal fluid samples. Results showed the treatment achieved sustained reduction of the harmful substance in participants who received the therapy.
Regulatory Clearance and Patient Access
Distribution of Fayuvi will be restricted to Qualified Treatment Centers, which are medical facilities specifically equipped and trained to deliver gene therapy products. Ultragenyx has announced plans to publish a comprehensive list of authorized facilities on a dedicated website within the coming days.
The biotechnology firm anticipates initial product shipments to qualified centers will occur within 30 to 60 days. According to company estimates, approximately 3,000 to 5,000 pediatric patients in accessible markets are currently diagnosed with Sanfilippo syndrome Type A.
Without therapeutic intervention, patients typically survive to approximately 15 years of age. This stark prognosis highlights the critical importance of this regulatory achievement for affected children and their families.
Production Capabilities and Company Growth
Production of Fayuvi takes place at two dedicated manufacturing sites located in Massachusetts and Ohio. This dual-facility approach was established to ensure reliable product availability as demand increases.
This regulatory success represents the company’s second gene therapy product to gain market authorization and brings its total FDA-approved products to six. Ultragenyx has systematically expanded its portfolio of rare disease treatments over recent years.
The FDA’s decision followed comprehensive evaluation of clinical trial results, including assessments of both cognitive function outcomes and biochemical indicators in study participants.
Pricing information for Fayuvi has not yet been disclosed by Ultragenyx, although gene therapies in this therapeutic category typically command substantial prices reflecting their one-time administration model and sophisticated manufacturing requirements.
Qualified Treatment Centers gained the ability to order the therapy immediately following Thursday’s regulatory announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
